Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.38 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.38 |
| ▸ | ADK | P55263 | 2/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3229166 | 0.87 | ADK (0.50) | ADORA2AMETTL3ADKPRMT5WDR77 | |
| SCHEMBL1736167 | 0.87 | METTL3 (0.40) | ADORA2AMETTL3METTL14ADKPRMT5 | |
| SCHEMBL1740552 | 0.86 | ADORA2A (0.43) | ADORA2AMETTL3METTL14ADKPRMT5 | |
| SCHEMBL1374265 | 0.84 | METTL3 (0.38) | METTL3METTL14ADK | |
| SCHEMBL1374267 | 0.84 | METTL3 (0.38) | METTL3METTL14ADK | |
| SCHEMBL1738408 | 0.84 | ADORA2A (0.55) | ADORA2APRMT5WDR77 | |
| SCHEMBL4430217 | 0.84 | ADORA2A (0.55) | ADORA2APRMT5WDR77 | |
| SCHEMBL13598781 | 0.84 | ADORA2A (0.55) | ADORA2APRMT5WDR77 | |
| SCHEMBL13598733 | 0.84 | ADORA2A (0.55) | ADORA2APRMT5WDR77 | |
| SCHEMBL12154906 | 0.81 | ADORA2A (0.39) | ADORA2AMETTL3METTL14ADKPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010015637-A1 | NEW ANTIVIRAL MODIFIED NUCLEOSIDES | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015637-A1 | NEW ANTIVIRAL MODIFIED NUCLEOSIDES | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |